Ahmad Ahsan, Imbisat Md Zaid, Khatoon Qurana
Urology, Indira Gandhi Institute of Medical Sciences, Patna, IND.
Surgery/Urology, Madhubani Medical College and Hospital, Madhubani, IND.
Cureus. 2024 Dec 31;16(12):e76678. doi: 10.7759/cureus.76678. eCollection 2024 Dec.
Introduction Balanitis xerotica obliterans (BXO) can cause phimosis, meatal stenosis, and urethral strictures. However, management of these conditions in BXO patients is difficult. Surgical interventions, with their own risks and complications, demonstrate higher rates of disease recurrence. Recently, topical applications of steroids and immunomodulators have been evaluated for their role in the management of urethral strictures associated with BXO. In this study, we evaluated the role of topical application of tacrolimus in urethral strictures associated with BXO. Materials and methods This was a prospective study on male patients having urethral strictures associated with BXO. Patients were thoroughly evaluated and advised topical application of 0.1% tacrolimus. They were then reevaluated at six weeks. If the effects of tacrolimus were found to be satisfactory, then patients were advised to continue this treatment for three months. After three months, the patients were again evaluated. At the time of each reevaluation, changes in uroflowmetry and International Prostate Symptom Score (IPSS) were noted. Results A total of 53 patients were included in this study. The mean values of pre- and post-tacrolimus maximum urinary flow rate on uroflowmetry(Q) were 12.00±1.43 m/s and 15.26±3.14 m/s, respectively (p<0.001). The mean values of pre- and post-tacrolimus IPSS scores were 18.55±2.28 and 13.04±4.72, respectively (p<0.001). Based on the results, the application of tacrolimus was found to be ineffective in those with strictures >2 cm in length. Of the 53 patients included in the study, 21 required surgical intervention, as their response to tacrolimus was unsatisfactory. Conclusion Topical application of tacrolimus is a safe and feasible treatment option for short-segment (≤2cm) urethral strictures associated with BXO.
引言
闭塞性干燥性龟头炎(BXO)可导致包茎、尿道口狭窄和尿道狭窄。然而,对BXO患者这些病症的治疗颇具难度。手术干预存在自身风险和并发症,疾病复发率较高。近来,已对类固醇和免疫调节剂的局部应用在与BXO相关的尿道狭窄治疗中的作用进行了评估。在本研究中,我们评估了他克莫司局部应用在与BXO相关的尿道狭窄治疗中的作用。
材料与方法
这是一项针对患有与BXO相关尿道狭窄的男性患者的前瞻性研究。对患者进行了全面评估,并建议局部应用0.1%他克莫司。然后在六周时对他们进行重新评估。如果发现他克莫司的效果令人满意,则建议患者继续该治疗三个月。三个月后,再次对患者进行评估。在每次重新评估时,记录尿流率和国际前列腺症状评分(IPSS)的变化。
结果
本研究共纳入53例患者。他克莫司治疗前后尿流率最大尿流率(Q)的平均值分别为12.00±1.43 m/s和15.26±3.14 m/s(p<0.001)。他克莫司治疗前后IPSS评分的平均值分别为18.55±2.28和13.04±4.72(p<0.001)。根据结果,发现他克莫司对长度>2 cm的狭窄患者无效。在纳入研究的53例患者中,21例因对他克莫司反应不佳而需要手术干预。
结论
他克莫司局部应用是治疗与BXO相关的短段(≤2cm)尿道狭窄的一种安全可行的治疗选择。